Deep Track, a Greenwich, Ct., investment management company that holds 13.5% of Dynavax's stock, pointed its finger at ...

Life sciences investment firm Deep Track Capital is launching a board fight at Dynavax Technologies , pressing for new ...

Good day, ladies and gentlemen, and welcome to the Dynavax Technologies fourth quarter and full year 2024 financial results ...

Life sciences investment firm Deep Track Capital is launching a board fight at Dynavax Technologies, pressing for new ...

Q4 2024 Earnings Call Transcript February 20, 2025 Dynavax Technologies Corporation reports earnings inline with expectations ...

Dynavax Technologies Corp (DVAX) reports record revenue for Heplisav-B, advances in vaccine programs, and strategic financial positioning despite rising R&D costs.

After privately vying for a change to Dynavax’s corporate strategy for months, life sciences investment firm Deep Track ...

Deep Track Capital, LP, (together with its affiliates, "Deep Track" or "we"), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) ("Dynavax", "DVAX" or the "Company"), ...

Dynavax reports record HEPLISAV-B revenue, 26% growth in 2024, and strong 2025 guidance. Insights on shingles vaccine progress & market expansion.

Dynavax Technologies Corporation ( NASDAQ: DVAX) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Paul Cox - Vice President, Investor Relations & Corporate Communications Ryan Spencer - ...

HEPLISAV-B net product revenue is expected in the range of $305M to $325M Discover the Best Stocks and Maximize Your Portfolio: See what ...

Dynavax Technologies (NASDAQ:DVAX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by William Blair in a note issued to investors on Friday,RTT News reports. William Blair also issued ...